-
3 weeks ago | 
ophthalmologymanagement.com | Joseph Jalkiewicz
To expand patient access to care, the Centers for Medicare and Medicaid Services (CMS) has begun asking ambulatory surgery centers (ASCs) to screen patients for “social drivers of health” (SDOH) that hinder access to care. However, groups that represent ASCs and surgeons, including those in ophthalmology, argue the measures are misplaced, citing insufficient staff and resources to assess and address these barriers.
-
2 months ago | 
ophthalmologymanagement.com | Joseph Jalkiewicz |Lindsey Getz |Matthew Baugh |Brandy Keys
https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://ophthalmologymanagement.com/media/rtgpwexe/cover_janfeb25.jpg Ophthalmology Management https://res.cloudinary.com/broadcastmed/image/fetch/e_unsharp_mask:70,q_auto,c_fill,f_auto,w_170,h_230/dpr_auto/https://ophthalmologymanagement.com/media/dvsf1uun/cover.jpg Contact Lens Spectrum...
-
Dec 31, 2024 | 
ophthalmologymanagement.com | Joseph Jalkiewicz
Sarah Le Goff, CEO of Eye Specialty Group in Memphis, Tenn., recalls the day she realized the group’s outdated electronic health record system (EHR) needed to be replaced. It was July of 2022, and as the company’s new operations director she was meeting with department managers across the five-location practice to hear their top grievances.
-
Oct 1, 2024 | 
ophthalmologymanagement.com | Jennifer Loh |Vance Thompson |Brent Kramer |Joseph Jalkiewicz
The Growth of a Multi-Location Practice
Vance Thompson, MD, and Brent Kramer, MD, discuss why they chose the multi-site route and how they made it work.
Improve Efficiency to Maximize Patient Time
Four MDs share some of their best tips for streamlining the patient experience and education process.
Capitalize on Ocular Surface Disease
This case study reveals how one practice successfully developed and executed a dry eye clinic business plan.
-
Oct 1, 2024 | 
ophthalmologymanagement.com | Brian M. Shafer |Joseph Jalkiewicz
Chances are good that many who practice ophthalmology for a living can relate to this line by Denzel Washington, which appeared in an essay the actor wrote some years ago: “I don’t care what you do for a living — if you do it well I’m sure there was someone cheering you on or showing the way.
-
Jul 31, 2024 | 
ophthalmologymanagement.com | Joseph Jalkiewicz
Ophthalmic ambulatory surgery centers (ASCs) face the ongoing challenge of managing costs while maintaining high-quality patient care. Anesthesia, a critical component of surgical procedures, represents a significant portion of these expenses, and ASCs are pulling out all the stops to hold them in check.
-
Jul 31, 2024 | 
ophthalmologymanagement.com | Joseph Jalkiewicz
In today’s evolving landscape, ophthalmic ambulatory surgery centers (ASCs) find themselves grappling with numerous challenges that threaten their financial viability. As costs rise and profits dwindle, ASC leaders must keep a sharp eye on many factors that contribute to profitability, including revenue cycle optimization, cost containment, and operational streamlining. Effective expense management is necessary to ensure a solid balance sheet in an economic environment where every penny counts.
-
Jul 31, 2024 | 
ophthalmologymanagement.com | Joseph Jalkiewicz
QLOSI offers clear solution to presbyopiaPreeya Gupta, MD, looks forward to the day she can give her patients the chance to take a break from the perpetual hunt for their reading glasses or the daily routine of cleaning and inserting contact lenses. That day isn’t far off. QLOSI (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription treatment for presbyopia that received FDA approval in October 2023, is expected to become commercially available later this year.
-
Jun 30, 2024 | 
ophthalmologymanagement.com | Joseph Jalkiewicz
Luminopia improves amblyopia treatment by improving patient compliance. Not long ago, the parents of a 5-year-old girl with amblyopia brought their child to David Epley, MD, looking for help. Despite the parents’ and Dr. Epley’s best efforts, unfortunately, they could not get the child to stick with treatment.
-
Feb 29, 2024 | 
ophthalmologymanagement.com | Joseph Jalkiewicz
XDEMVY is the first and only treatment that targets the parasites that cause the disease. The patient, a woman in her 30s, visited Brandon Ayres, MD, seeking help for yet another flare-up of blepharitis. Despite years of symptomatic treatment with warm compresses, lid scrubs, ointments, steroids, ocular anti-inflammatories, even tea tree oil, the condition simply would not go away.
